A530082C11Rik Inhibitors
A530082C11Rik inhibitors belong to a unique category of chemical compounds designed to specifically target and inhibit the A530082C11Rik protein, which is encoded by the A530082C11Rik gene. This protein, whose function has not been extensively characterized, is part of a larger network of intracellular signaling and regulatory proteins. The inhibition of A530082C11Rik likely plays a role in modulating key cellular pathways that involve protein-protein interactions, enzymatic activities, or other intracellular signaling cascades. Inhibitors targeting this protein are engineered to bind with high specificity to critical active or allosteric sites, effectively modulating the protein's activity or preventing its interactions with other molecular entities. Such modulation can lead to changes in downstream processes such as gene expression, signal transduction, or cellular metabolism.
Chemically, A530082C11Rik inhibitors may exhibit a wide variety of structural features depending on their mechanism of action. They might include small molecules, peptides, or other synthetic compounds that are capable of targeting particular domains or conformations of the A530082C11Rik protein. The structural specificity and the binding affinity of these inhibitors are typically enhanced through rational drug design strategies, high-throughput screening, or molecular docking studies. In studying the biochemical behavior of A530082C11Rik inhibitors, researchers focus on key parameters such as their selectivity, molecular stability, interaction kinetics, and effects on protein folding or post-translational modifications. These inhibitors also serve as important tools in deciphering the biological role of A530082C11Rik and in advancing fundamental research into its molecular functions within complex cellular environments.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the formation of dolichol-linked oligosaccharides. As solute carrier family 35, member E2 is a membrane protein potentially undergoing glycosylation, tunicamycin would inhibit its proper folding and trafficking to the membrane, leading to functional inhibition. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which would inhibit the post-translational modification and trafficking of solute carrier family 35, member E2, thus impairing its function. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin acts as an ionophore that disrupts ion gradients necessary for protein trafficking in Golgi. This disruption can inhibit the correct localization of solute carrier family 35, member E2, thus inhibiting its function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, an enzyme involved in the processing of N-linked glycans in the Golgi. This would prevent the proper glycosylation and function of solute carrier family 35, member E2. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits glucosidases involved in the trimming of glucose residues from N-linked oligosaccharides on glycoproteins. Inhibiting this process would impair the function of solute carrier family 35, member E2 by preventing proper folding and trafficking. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidases, which are involved in glycoprotein processing. This inhibition would affect the folding and function of solute carrier family 35, member E2. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin inhibits mannosidase I, which is critical for the maturation of N-linked glycans. This would affect the glycosylation and function of solute carrier family 35, member E2. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine inhibits mannosidase I, preventing the proper processing of N-linked glycans in the ER and Golgi. This would result in the functional inhibition of solute carrier family 35, member E2. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal selectively inhibits phosphatase complexes that dephosphorylate eIF2α, leading to the accumulation of misfolded proteins in the ER. This stress can prevent the proper folding and function of solute carrier family 35, member E2. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I inhibits the ER-associated degradation (ERAD) pathway, which could lead to the accumulation of misfolded solute carrier family 35, member E2 proteins, inhibiting their proper function. | ||||||